

DARBY & DARBY

Professional Corporation

NEW YORK
805 Third Avenue
New York, NY 10022
Tel: 212.527.7700
Fax: 212.753.6237

SEATTLE
1191 Second Avenue
Seattle, WA 98101
Tel: 206.262.8900
Fax: 206.262.8901

INTELLECTUAL PROPERTY LAW

DATE: September 26, 2003

FILE #: 01225/100G584-US2

FROM: Anna Löqvist, Ph.D.

E-MAIL: alovqvist@darbylaw.com

PHONE: 212.836.3747

NO. OF PAGES: 12
(including cover page)

703.746.5195	Dr. Karen Canella U.S.P.T.O., Art Unit 1642	No
--------------	--	----

COMMENTS: Dear Examiner Canella:

Per your phone conversation with Paul Fehlner and me on 9/23/2003, enclosed is a revised set of the claims described in the draft Examiner's Amendment faxed to us on 9/17/2003. Apart from some indicated typographical corrections, our revisions are:

- Claims 13-20: Shown as "cancelled" as per our 6/9/2003 amendment;
- Claims 21 & 23: Add that cells/equivalents are "autologous" and amend to broader dose range in second composition (see p. 21 for support);
- Claim 43: Re-instate, change dependency to claim 21;
- Claims 21 & 46: Delete the limitation in step (b) of "4-7 days ... treatment";
- Claims 46-50: Re-instate with claim 46 being similar to claim 23 apart from not reciting "autologous", and with claim 50 amended accordingly;

PLEASE RETURN TO BETSY ROSADO

*** IF YOU DO NOT RECEIVE ALL PAGES, PLEASE TELEPHONE US IMMEDIATELY AT 212.527.7774**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THIS DOCUMENT AT NO COST TO YOU. THANK YOU.

{M:\1225\1g584us2\00061371.DOC *****}

Received from <212 753 6237> at 9/26/03 3:25:35 PM [Eastern Daylight Time]

- Claims 47-49: Change dependency from claim 46 to claim 21;
- Claim 55: Delete that cells/equivalents are "autologous" and amend to broader dose range in second composition.
- Claim 57: Added, similar to claim 32 but depending from claim 23.
- For your convenience, we are sending you two copies, one "mark-up" of your draft Examiner's Amendment, and one "version showing changes made".
- All claims where we have suggested corrections or changes are indicated as "Revised".

Please let us know if there are any remaining issues that you would like to discuss. As I will be out of the office for most part of next week, please contact Paul Fehlner instead (212-527-7865).

Best regards,

/Anna

* IF YOU DO NOT RECEIVE ALL PAGES, PLEASE TELEPHONE US IMMEDIATELY AT (212) 527-7777

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE SO THAT WE CAN ARRANGE FOR THE RETRIEVAL OF THIS DOCUMENT AT NO COST TO YOU. THANK YOU.

{M:\1225\lg584us2\00061371.DOC [REDACTED] } -2-